Meaningful progress has been realized in the treatment of metastatic renal cell carcinoma with the recent approval of a number of new agents; more new agents are on the horizon.
Despite the recent completion of many clinical trials that have changed or will change practice, many questions remain. In this manuscript, we highlight the most noteworthy developments in the first- and second-line treatment of metastatic renal cell carcinoma, as these are the areas of greatest change. We also emphasize ongoing trials and those areas that are most in need of study in order to move the field forward. Although more data are needed, exciting progress is being made.
Written by:
Hirsch BR, George DJ, Harrison MR. Are you the author?
Duke University Medical Center, Durham, North Carolina.
Reference: Clin Adv Hematol Oncol. 2014 Mar;12(3):163-71.
PubMed Abstract
PMID: 24927264
UroToday.com Renal Cancer Section
